News · Cryoport, Inc. (CYRX) · Industrials

Cryoport rises 19.0% after quarterly results and raised revenue guidance

Session of November 6, 2026 · Published November 7, 2026 · 4 min read

What happened

Cryoport (CYRX) rose 19.0% on November 6, 2026, because of third-quarter results and a raised full-year revenue guidance. The company reported third-quarter 2026 revenue of $50.2 million, up 14% year-over-year, and a quarterly loss of $0.25 per share, according to Seeking Alpha and Zacks Investment Research. After the report, Cryoport raised its full-year 2026 revenue guidance to a range of $197 million to $199 million, citing strong demand for its cell and gene therapy services and for its cryogenic product lines, according to MarketBeat and PRNewsWire.

Closing price over the last 30 trading sessions. On November 6, 2026, CYRX closed at $19.10, up 19.0% on the day and 9.9% higher than 30 sessions earlier.

How big was the move

The stock closed at $19.10 and rose 19.0% on the day. Trading volume was 2.5 times its 20-day average, and the session was 5.5 times a typical daily move for this stock. The move was 18.0 percentage points better than the Industrials sector median, while the S&P 500 rose 0.3% on the day. Over the last five sessions the stock rose 10.5% even as the S&P 500 fell 2.7%.

Each bar is one day's price change; the outlined bar is November 6, 2026. A typical daily move over the past year was 3.0%, so the latest move equals 6.4 times that. Moves outside the dashed lines (about 6.0%) are unusual.

The session followed an opening that was opened 9.0% above the previous close, reflecting early enthusiasm. In the past five years the stock had 8 sessions with a gain of at least 19.0%; twenty trading days later the median result was a decline of 3.3%, and 4 of 8 were higher.

The technical picture

Technically the stock showed strong momentum. The stock was 9.8% above its 20-day moving average and 12.5% above its 50-day moving average, with the 50-day average above the 200-day average, a sign of an established uptrend. It was 42.0% above its 200-day moving average and had been above that level for 151 consecutive trading days.

Closing price over the past year. CYRX ends the period at its 52-week high, above its 50-day average ($16.98) and above its 200-day average ($13.45).

Momentum indicators were consistent with the price action. The Relative Strength Index (14 days) was 61, inside a neutral range, and price momentum is evident: change over one month rose 13.0% and change over three months rose 28.9%. The stock was 2.2% below the 52-week high, and over one year it rose 123.9%, 115.4 percentage points ahead of the S&P 500. Volatility was 54% annualized over 60 days, lower than 83% of its own readings over five years, and the stock has a beta of 1.17, so it tends to move more than the market.

Fundamentals and valuation

For the four quarters through September 30, 2026, revenue was $192.4 million, which grew 1.1% from a year earlier. Diluted earnings per share were $-0.89, with earnings per share growth from a year earlier that fell 176.1%. Gross margin was 46.9% (a year earlier: 46.6%), and operating margin was 20.0% (a year earlier: 22.6%). Free-cash-flow margin was 9.5% and return on invested capital was 5.5%.

Quarterly revenue by period end. The latest quarter brought $50M, 13.5% more than the same quarter a year earlier.

The balance sheet showed net cash of $47.7 million, and share count over one year increased by 1.1%. Valuation by free cash flow shows a free-cash-flow yield of 2.1%. Those figures underline a mixed picture: revenue growth has slowed compared with recent quarterly volatility, while the company maintains positive cash on the balance sheet and modest free-cash-flow generation. PromtFinance scores reflect the contrast: Momentum 100 (Exceptional) versus Value 10 (Very weak) and Growth 18 (Very weak).

Earnings and analyst expectations

The last report, issued November 5, 2026, showed earnings per share of $-0.25 against $-0.18 expected, 41.4% below estimates. The firm had consecutive quarters beating estimates: 0, and average surprise over the last four reports was 17.6% below estimates. Typical two-day reaction after recent reports was that the stock fell 0.2%.

Diluted earnings per share by quarter. The latest quarter shows -$0.25, against -$0.18 in the same quarter a year earlier.

Analysts covering the stock put the consensus price target at $20.19, 5.7% above the closing price, based on 19 analysts whose ratings produce a consensus rating of Buy. Seventy-nine percent of those ratings are Buy or Strong Buy. The next scheduled report is March 2, 2027.

What to watch

Third-quarter 2026 results: revenue of $50.2 million, up 14% year-over-year, and quarterly loss of $0.25 per share (reported November 5, 2026).
Updated full-year 2026 revenue guidance: $197 million to $199 million (announced after the November report).
Trading activity: trading volume was 2.5 times its 20-day average on November 6, 2026.
Momentum and volatility: PromtFinance Momentum score 100 (Exceptional) and volatility 54% annualized over 60 days, lower than 83% of its own readings over five years.
Analyst consensus: consensus price target $20.19, 5.7% above the closing price, with 79% of ratings Buy or Strong Buy.

Full CYRX analysis: scores, chart and financials →